1 month Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor FitzgeraldMarketBeat
Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday.
X